Peripheral neuropathy associated with ipilimumab: a report of 2 cases
I Thaipisuttikul, P Chapman, EK Avila - Journal of Immunotherapy, 2015 - journals.lww.com
Ipilimumab, a monoclonal antibody targeting human cytotoxic T-lymphocyte–associated
antigen 4, was approved by the FDA and European Medicines Agency for the treatment of
metastatic melanoma. Immune-related adverse effects can occur with the use of this agent,
but peripheral nervous system problems are rare. We report 2 cases of ipilimumab-induced
polyneuropathy.
antigen 4, was approved by the FDA and European Medicines Agency for the treatment of
metastatic melanoma. Immune-related adverse effects can occur with the use of this agent,
but peripheral nervous system problems are rare. We report 2 cases of ipilimumab-induced
polyneuropathy.
